DrugPatentWatch Database Preview
Investigational Drug Information for Alisertib
Email this page to a colleague
What is the development status for investigational drug Alisertib?
Alisertib is an investigational drug.
There have been 57 clinical trials for Alisertib.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 11th 2012.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are two hundred and nineteen US patents protecting this investigational drug and two international patents.
Summary for Alisertib
| US Patents | 219 |
| International Patents | 2,343 |
| US Patent Applications | 589 |
| WIPO Patent Applications | 467 |
| Japanese Patent Applications | 92 |
| Clinical Trial Progress | Phase 3 (2012-06-11) |
| Vendors | 75 |
Recent Clinical Trials for Alisertib
| Title | Sponsor | Phase |
|---|---|---|
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Alisertib
Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib
US Patents for Alisertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Alisertib | ⤷ Try it Free | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try it Free |
| Alisertib | ⤷ Try it Free | Pyrrolidinone derivatives as MetAP-2 inhibitors | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try it Free |
| Alisertib | ⤷ Try it Free | Aurora A kinase inhibitor | Eli Lilly and Company (Indianapolis, IN) | ⤷ Try it Free |
| Alisertib | ⤷ Try it Free | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try it Free |
| Alisertib | ⤷ Try it Free | .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof | Quadriga Biosciences, Inc. (Los Altos, CA) | ⤷ Try it Free |
| Alisertib | ⤷ Try it Free | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Alisertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Alisertib | Australia | AU2011261185 | 2030-06-03 | ⤷ Try it Free |
| Alisertib | Australia | AU2015275321 | 2030-06-03 | ⤷ Try it Free |
| Alisertib | Australia | AU2018204179 | 2030-06-03 | ⤷ Try it Free |
| Alisertib | Australia | AU2020202752 | 2030-06-03 | ⤷ Try it Free |
| Alisertib | Brazil | BR112012030625 | 2030-06-03 | ⤷ Try it Free |
| Alisertib | Canada | CA2800913 | 2030-06-03 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
